Table III.
Change from baseline in Wisconsin Upper Respiratory Symptom Survey (WURSS-21) scores (modified intent-to-treat population).
Guaifenesin/pseudoephedrine (n = 591) | Placebo (n = 588) | P value* | |
---|---|---|---|
Overall total WURSS-21 score | |||
Mean change from baseline to Day 4 | 40.0 | 36.4 | 0.024 |
Mean change from baseline to Day 8 | 68.0 | 65.4 | 0.085 |
Total WURSS-21 symptom score | |||
Mean change from baseline to Day 4 | 19.4 | 17.7 | 0.013 |
Mean change from baseline to Day 8 | 33.4 | 32.0 | 0.165 |
Total WURSS-21 functional score | |||
Mean change from baseline to Day 4 | 16.2 | 14.6 | 0.050 |
Mean change from baseline to Day 8 | 27.7 | 26.8 | 0.056 |
Difference between treatment groups in change from baseline is based on ANCOVA with treatment, region, baseline total WURSS-21 functional score, antibiotic use, and treatment by antibiotic use terms in the model.